tbuckley/cabot-search huggingface dataset:
Liver Extract in Toxemias of Pregnancy.—
Journal: JAMA (1928)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hormone hypothesis joins factors under study in motion sickness
Authors: K. Simmons
Journal: JAMA (1984)

Anyone who has ever felt the grip of motion sickness—whether on land, at sea, or in the air—has likely wondered, "Why me?". The answer lies in the fact that some persons are more susceptible than others, says Randall Lee Kohl, PhD, staff scientist at Universities Space Research Association, Houston, a contractor for the National Aeronautics and Space Administration (NASA). But Kohl has taken the idea of susceptibility a step further by correlating it with the hormonal response to motion sickness. "It appears that those who are less susceptible to motion sickness show higher elevations—upon exposure to [factors causing] motion sickness—of such hormones as adrenaline [epinephrine], ACTH [adrenocorticotropic hormone], and possibly norepinephrine," Kohl reported in Atlanta at the recent meeting of the American Society for Clinical Pharmacology and Therapeutics. "There also appears to be some indication that resting levels of these hormones may be elevated in people who have a lower
THE PATHOGENESIS OF CHOREA.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
"SOMNOFORM"
Authors: Yandell Henderson
Journal: JAMA (1930)

<h3>To the Editor:</h3> —I have recently received from the Stratford-Cookson Company of Philadelphia an advertisement of "Somnoform." The formula given for "Somnoform" is chloride of ethyl, 83 per cent; chloride of methyl, 16 per cent; bromide of ethyl, 1 per cent. Below this formula it is asserted that "the record of Somnoform for safety is without equal." If such is the case the record must be regarded as a pure piece of good fortune, for two at least of the ingredients of "Somnoform" have a toxicity which renders them unfit for use as anesthetics. The poisonous character of methyl chloride has been sufficiently demonstrated by the refrigerator cases in Chicago. Although the amount of ethyl bromide in the mixture is small, there are general grounds for believing that the toxicity of the substance is high. Ethyl chloride is, of course, a commonly used and convenient anesthetic, but it possesses to
Infection From Intravenous "Scalp-Vein" Needles in a Susceptible Population
Authors: Stanley Lowenbraun
Journal: JAMA (1970)

Intravenous indwelling scalp-vein needles were cultured in a population with neoplastic disease. Twenty-four of the 74 needles cultured were positive; microorganisms generally considered pathogenic grew from 7 of these needles. The latter organisms included<i>Staphylococcus aureus</i>,<i>Pseudomonas aeruginosa</i>,<i>Candida albicans</i>, α-hemolytic Streptococcus, and group D<i>Streptococcus</i>. Infected scalpvein needles were the bacteriologic source in one case of septicemia and one case of cellulitis. There was a trend toward increasing incidence of growth with increasing duration of needle placement.
Early ST-variability predicts thrombi in the infarct related artery. A report from the ASSENT PLUS ST-monitoring substudy Per Johanson, Monica Eriksson, Gerd K�llstr�m, Gunilla Norman, Jenny R�ssberg. Ann-Marie Svensson, Helena Svensson, Mikael Dellborg. Sahlgrenska University Hospital/ �stra, G�teborg, Sweden
Journal: Journal of the American College of Cardiology (2001)
Evaluating the performance of a large computerized information system
Authors: F. W. Lancaster
Journal: JAMA (1969)

The Medical Literature Analysis and Retrieval System (MEDLARS), in operation at the National Library of Medicine (NLM), is a multipurpose system, a prime purpose being the production of<i>Index Medicus</i>and other recurring bibliographies.<sup>1</sup>This two-year study concentrated on the evaluation of the demand search function of MEDLARS (ie, the conduct of retrospective literature searches in response to specific demands).<sup>2</sup> The base of the retrospective search module consists of approximately 800,000 citations to biomedical journal articles input to the January 1964 and subsequent issues of the monthly<i>Index Medicus</i>. These articles have been indexed by means of a controlled vocabulary of<i>Medical Subject Headings</i>(<i>MeSH</i>). Over 3000 demand searches are now formulated annually at the NLM, additional searches being handled at regional MEDLARS centers in the United States, in the United Kingdom, and in Sweden. Approximately 2,300 scientific journals are indexed regularly, one third exhaustively ("depth journals") at
Lyme Disease—United States, 1987 and 1988
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract P3-05-02: Pathological assessment of discordant cases for molecular (BluePrint and MammaPrint) versus clinical subtypes for breast cancer among 621 patients from the EORTC 10041/BIG 3–04 (MINDACT) trial
Authors: G Viale, L Slaets, F de Snoo, Veer L van't, E Rutgers, M Piccart, J Bogaerts, J van den Akker, L Stork-Sloots, K Engelen, L Russo, P Dell'Orto, F Cardoso
Journal: Cancer Research (2012)

Abstract Background: Biology has become the main driver of breast cancer therapy. Intrinsic biological subtypes by gene expression profiling have been identified. Pathology can be used to define surrogates of these subtypes but these are not always concordant, which may lead to different treatment plans. We investigated the concordance between BluePrint and MammaPrint (microarray-based) breast cancer subtypes and pathological surrogates (based on ER, PR, HER2 &amp; Ki67). Methods: Using available data (centrally assessed pathology and genomics) from the MINDACT pilot phase [Rutgers et al. EJC 2011] 621 tumors were analyzed. Patients were classified according to 4-category based pathology (ER, PR, HER2 and Ki67); additionally, classification was performed adhering to the recent St. Gallen recommendations [Goldhirsch et al. 2011], which recognizes an additional category (Luminal B HER2+). Based on BluePrint and MammaPrint 4 subtypes are formed: Luminal A (Luminal-type/MammaPrint Low Risk); Luminal B (Luminal-type/MammaPrint High Risk); HER2-type; and Basal-type. This study is an analysis of discordant patient groups (i.e. clinical HER2+/BluePrint Luminal-type; clinical Hormone Receptor (HR)-positive/BluePrint Basal-type) providing comparison of centrally assessed tumor heterogeneity as well as comparison of quantified ER, PR and HER2 results. Results: Ki67 is often used as biomarker to distinguish Luminal A from Luminal B subgroups. The concordance between MammaPrint and centrally assessed Ki67 in Luminal-type patients is 71%, with a κ score of 0.35 (95% CI 0.26–0.45) indicating that Ki67 and MammaPrint cannot reliably substitute for each other. There is a relatively large group of clinical HER2+ cases that are BluePrint Luminal-type (29 out of 76; 38%) indicating that tumor expression of the Luminal profile is dominant compared with expression of the HER2 profile. These patients have high IHC ER results and fall into the group that St Gallen separately defines as Luminal B HER2-type. These patients may have lower response to trastuzumab [von Minckwitz et al. JCO 2012]. 12 out of 76 BluePrint Basal-type patients are clinical HR+. These patients have low centrally assessed IHC ER and PR expression (≥1% and &amp;lt;10%). Conclusions: Marked differences are observed between BluePrint and MammaPrint (microarray based) breast cancer subtypes and centrally re-assessed pathological surrogates (based on ER, PR, HER2 &amp; Ki67). The greatest discordance is seen in the sub-stratification of Luminal patients, and in the HR+/HER2+ patients. The observed subtype discrepancies may have an important impact on treatment decision making. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P3-05-02.
Cyclosporine-ketoconazole combination offers promise in reducing antirejection therapy costs
Authors: T. Randall
Journal: JAMA (1990)

RESEARCHERS have wed the prince of immunosuppressive drugs, cyclosporine, to a common antifungal medication, ketoconazole, and this union has been shown to slash the costs of antirejection therapy in patients who have undergone kidney transplantation by more than 80%. Historically, Sandoz Pharmaceuticals Corporation (East Hanover, NJ), the manufacturer of cyclosporine, has discouraged the concomitant use of ketoconazole (Nizoral, Janssen Pharmaceutica Inc, Piscataway, NJ) because it creates dangerously high cyclosporine levels in the blood. But the kidney transplant team at the University of Cincinnati (Ohio) reports it has harnessed this property of ketoconazole to allow a reduction in the cyclosporine dosage by 70% in the first week and up to 88% after 18 months. "If found to be safe and effective, this drug interaction has enormous potential for reductions in the costs associated with organ transplantation," says Roy First, MD, director of the University of Cincinnati Medical Center's kidney transplantation section.
SOME DISORDERS OF THE SENSE OF SMELL.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
MEXICO
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The social value of professional accreditation
Authors: F. G. Dickey
Journal: JAMA (1970)

In speaking to this topic, it would be simple and perhaps expedient to say that accreditation in a professional field has social value because it serves to protect society. It ostensibly protects society from mediocrity in the education process, and it protects students from being hoodwinked or fleeced. Accreditation protects the profession itself from being downgraded by the entry of ill-prepared practitioners. All of these things are part and parcel of the whole concept of accreditation, but to understand fully the social value of professional accreditation, one must place the concept within the matrix of our national background and also within the context of today's problems. One of the fundamental and basic traditions of this nation has been the freedom of higher education from political interference and dictation. Largely because of this tradition of freedom of education, accreditation by nongovernmental agencies has developed in the United States. This situation is
Improvement in Social Competence With Short-Term Atypical Antipsychotic Treatment: A Randomized, Double-Blind Comparison of Quetiapine Versus Risperidone for Social Competence, Social Cognition, and Neuropsychological Functioning
Authors: Philip Harvey
Journal: American Journal of Psychiatry (2006)

Objective: While neuropsychological test performance is correlated with social outcomes in patients with schizophrenia, there is little evidence to date that changes in neuropsychological performance are associated with changes in these outcomes. As part of an efficacy and tolerability study of atypical antipsychotics, the authors used a performance-based measure of social competence as a short-term outcome measure and examined the correlations between changes in social competence and improvements on neuropsychological tests. Method: Patients with schizophrenia were randomly assigned in a 1:1 ratio to receive treatment with either quetiapine (dose range: 200–800 mg/day) or risperidone (dose range: 2–8 mg/day) for an 8-week period. Results: Of 673 patients initially randomized, 289 had baseline and endpoint neuropsychological and functional competence data. Scores on the performance-based measure of social competence significantly improved with both treatments, as did a number of aspects of neuropsychological performance. Improvements in several aspects of neuropsychological performance were correlated with the extent of improvement in social competence. There were no overall differences between the treatments in their impact on social competence and neuropsychological performance. Conclusions: Short-term treatment with both quetiapine and risperidone resulted in improvements in social competence, with these improvements associated with improvements on some of the neuropsychological measures. In addition to their clinical importance, these results support the use of performance-based competence assessments as outcome measures in clinical trials.
Correction: Cardiorespiratory Fitness, Impaired Fasting Glucose, and Type 2 Diabetes
Journal: Annals of Internal Medicine (1999)

Corrections7 September 1999Correction: Cardiorespiratory Fitness, Impaired Fasting Glucose, and Type 2 DiabetesFREEhttps://doi.org/10.7326/0003-4819-131-5-199909070-00020 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail In an article on cardiorespiratory fitness and impaired fasting glucose and type 2 diabetes (1), the last sentence of the second full paragraph on page 93 should read “A decrease in fitness of 1 MET was associated with a 20% (CI, 10% to 20%) increase in risk for impaired fasting glucose and a 28% (CI, 12% to 47%) increase in risk for type 2 diabetes,” not an “increase in fitness of 1 MET … .”Reference1. Wei M, Gibbons LW, Mitchell TL, Kampert JB, Lee CD, Blair SN. The association between cardiorespiratory fitness and impaired fasting glucose and type 2 diabetes mellitus in men. Ann Intern Med. 1999;130:89-96. LinkGoogle Scholar Comments0 CommentsSign In to Submit A Comment PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoThe Association between Cardiorespiratory Fitness and Impaired Fasting Glucose and Type 2 Diabetes Mellitus in Men Ming Wei , Larry W. Gibbons , Tedd L. Mitchell , James B. Kampert , Chong D. Lee , and Steven N. Blair Metrics Cited byA Guide to Exercise Prescription 7 September 1999Volume 131, Issue 5Page: 394KeywordsGlucoseType 2 diabetes ePublished: 15 August 2000 Issue Published: 7 September 1999 Copyright & PermissionsCopyright © 1999 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Comparative Inhalation Teratogenicity of Four Glycol Ether Solvents and an Amino Derivative in Rats
Authors: B. K. Nelson, James V. Setzer, W. Stephen Brightwell, Patricia R. Mathinos, Maureen H. Kuczuk, Timothy E. Weaver, Phillip T. Goad
Journal: Environmental Health Perspectives (1984)

Previous research demonstrated the inhalation teratogenicity of the solvent 2-ethoxyethanol in rats and rabbits. As this is one of a class of widely used industrial solvents, we investigated the teratogenicity of five structurally related compounds. Each chemical was vaporized and administered to approximately 15 pregnant rats in one to three concentrations for 7 hr/day on gestation days 7 to 15, and dams were sacrificed on day 20. Fetuses were individually weighed, and two-thirds of them were fixed in Bouin's solution and examined for soft-tissue anomalies. The other one-third were fixed in alcohol, stained with Alizarin Red and examined for skeletal defects. Data were analyzed on a litter basis; three solvents were compared with a pooled group (N = 34) of sham-exposed controls, and the remaining two were compared with a group of 15 controls. At concentrations which were apparently not maternally toxic, 2-methoxyethanol was highly embryotoxic, producing complete resorptions at 200 ppm; increased resorptions, reduced fetal weights and skeletal and cardiovascular defects occurred at both 100 and 50 ppm. 2-ethoxyethyl acetate at 600 ppm induced complete resorption of litters; 390 ppm reduced fetal weights and induced skeletal and cardiovascular defects, but only a single defect was observed at 130 ppm. 2-Butoxyethanol evidenced slight maternal toxicity at 200 ppm but produced no increase in congenital defects at that concentration. Neither 2-(2-ethoxyethoxy)ethanol (100 ppm) nor 2-methylaminoethanol (150 ppm) was maternally toxic or embryotoxic. In summary, shorter alkyl chained glycol ethers produced greater embryotoxicity than those having longer chains, and the ester produced effects equivalent to the ether, both patterns predictable from the biochemical literature.
Hormone replacement therapy (HRT) in women with previously treated primary breast cancer. Update XI
Authors: A. Z. Bluming
Journal: Journal of Clinical Oncology (2005)

787 Background: To assess the incidence of contralateral or recurrent breast cancer among women prospectively treated with HRT after initial breast cancer diagnosis and treatment. Methods: A community-based, prospective, single-arm, pilot study of HRT among 238 women with previously treated primary breast cancer. Results: Median duration of HRT is 78+ months (range 12+ -148+). Median interval from initial surgery to initiation of HRT is 52 months (range 2–361 months). Follow-up to date is 100%. Actuarial disease-free survival (DFS), disease-specific survival (DSS), & median duration of HRT (months) by stage are listed in the Table. *T0N0: 4 contralateral tumors 3 LCIS recurred locally after lumpectomy alone. 2 DCIS recurred locally after lumpectomy/RT 1 distant recurrence - liver. **T1N0: 7 contralateral tumors. 7 local recurrences after lumpectomy/RT 7 distant recurrences - 3 lung, 2 liver, 2 bone - 3 died ***T2N0: 2 local recurrences after lumpectomy/RT 2 distant recurrences - both lung - 1 died ****T1N1: 3 contralateral tumors 2 local recurrences after lumpectomy/RT 2 distant recurrences - 1 bone, 1 supraclav node - 1 died *****T2–3N1: 1 local recurrence after lumpectomy/RT 2 distant recurrences - both bone metastases -1 died One hundred and four patients have stopped HRT (44%), 49 because of anxiety about taking HRT (21%), 45 because of breast cancer development (19%), 3 because of the development of non-breast cancers, 3 died of nonmalignant disease, 3 because of HRT-associated symptoms, and 1 because of pulmonary emboli without clinical phlebitis. Actuarial DFS to 20 years for T1N0 patients was 72% (DSS=95%) versus 60% (DSS=92%) for comparable T1N0 patients who did not receive HRT. Conclusions: No evidence to date of increased development, recurrence or of breast cancer-related death associated with post diagnosis HRT. No significant financial relationships to disclose.